CRISPR Medicine News - 3 February 2021 | Clinical Trial Update - Meganuclease-Edited CAR T-Cell Therapies - CRISPR Medicine

CRISPR QC pioneers streamlined and automated CRISPR quality control tools to accelerate research while improving accuracy and performance.


Clinical Trial Update - Meganuclease-Edited CAR T-Cell Therapies

This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy. The latest trial is sponsored by Precision BioSciences (US) and it will evaluate the safety and efficacy of PBCAR19B, a gene-edited allogeneic (donor-derived) anti-CD19 CAR T cell therapy for relapsed or refractory Non-Hodgkin lymphoma. Read the update right here.

Pick of the Month

Dr Matthew Porteus, Stanford University, spoke to us on the CRISPR clinical trials to cure Sickle Cell Disease patients. Dr Matthew Porteus is a co-founder of Graphite Bio and a scientific founder of CRISPR Therapeutics. He gave us his perspective on both CRISPR therapies - Graphite Bio directly addressing the disease mutation and CRISPR Therapeutics taking a clever workaround. Please read it here: There Are Now Two Pushes to Treat Sickle Cell Disease With CRISPR.

Career CRISPR Medicine

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at We love hearing from readers!

Happy Reading!


p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.